Martinuzzi Emanuela, Barbosa Susana, Courtet Philippe, Olié Emilie, Guillaume Sébastien, Ibrahim El Chérif, Daoudlarian Douglas, Davidovic Laetitia, Glaichenhaus Nicolas, Belzeaux Raoul
Université Côte d'Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Clinical Research Unit, Valbonne, France.
Centre Hospitalier Universitaire de Montpellier, Institut National de la Santé et de la Recherche Médicale, Ho^pital Lapeyronie, Department of Emergency Psychiatry and Acute Care, Montpellier, France.
Brain Behav Immun Health. 2021 Mar 10;13:100232. doi: 10.1016/j.bbih.2021.100232. eCollection 2021 May.
Bipolar disorder (BD) diagnosis currently relies on assessment of clinical symptoms, mainly retrospective and subject to memory bias. BD is often misdiagnosed as Major Depressive Disorder (MDD) resulting in ineffective treatment and worsened clinical outcome. The primary purpose of this study was to identify blood biomarkers that discriminate MDD from BD patients when in a depressed state. We have used clinical data and serum samples from two independent naturalistic cohorts of patients with a Major Depressive Episode (MDE) who fulfilled the criteria of either BD or MDD at inclusion. The discovery and replication cohorts consisted of 462 and 133 patients respectively. Patients were clinically assessed using standard diagnostic interviews, and clinical variables including current treatments were recorded. Blood was collected and serum assessed for levels of 31 cytokines using a sensitive multiplex assay. A penalized logistic regression model combined with nonparametric bootstrap was subsequently used to identify cytokines associated with BD. Interleukin (IL)-6, IL-10, IL-15, IL-27 and C-X-C ligand chemokine (CXCL)-10 were positively associated with BD in the discovery cohort. Of the five cytokines identified as discriminant features in the discovery cohort, IL-10, IL-15 and IL-27 were also positively associated with BD in the replication cohort therefore providing an external validation to our finding. Should our results be validated in a prospective cohort, they could provide new insights into the pathophysiological mechanisms of mood disorders.
双相情感障碍(BD)的诊断目前依赖于临床症状评估,主要是回顾性的,且存在记忆偏差。BD常被误诊为重度抑郁症(MDD),导致治疗无效和临床结局恶化。本研究的主要目的是确定在抑郁状态下能够区分MDD患者和BD患者的血液生物标志物。我们使用了来自两个独立自然主义队列的临床数据和血清样本,这些队列中的重度抑郁发作(MDE)患者在纳入时符合BD或MDD的标准。发现队列和验证队列分别由462名和133名患者组成。使用标准诊断访谈对患者进行临床评估,并记录包括当前治疗在内的临床变量。采集血液,使用灵敏的多重检测法评估血清中31种细胞因子的水平。随后使用惩罚逻辑回归模型结合非参数自助法来确定与BD相关的细胞因子。在发现队列中,白细胞介素(IL)-6、IL-10、IL-15、IL-27和C-X-C配体趋化因子(CXCL)-10与BD呈正相关。在发现队列中确定为判别特征的五种细胞因子中,IL-10、IL-15和IL-27在验证队列中也与BD呈正相关,从而为我们的发现提供了外部验证。如果我们的结果在前瞻性队列中得到验证,它们可能会为情绪障碍的病理生理机制提供新的见解。